scPharmaceuticals’ (SCPH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $18.00 target price on the stock.

scPharmaceuticals Stock Down 0.3 %

Shares of NASDAQ SCPH opened at $3.00 on Thursday. The stock has a market capitalization of $150.12 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. scPharmaceuticals has a 12-month low of $2.75 and a 12-month high of $5.65. The firm’s 50-day moving average price is $3.27 and its 200-day moving average price is $3.78. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The company had revenue of $12.15 million for the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. On average, equities research analysts anticipate that scPharmaceuticals will post -1.53 EPS for the current fiscal year.

Hedge Funds Weigh In On scPharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its stake in scPharmaceuticals by 20.1% in the 4th quarter. Rhumbline Advisers now owns 42,554 shares of the company’s stock worth $151,000 after acquiring an additional 7,112 shares in the last quarter. Rubric Capital Management LP boosted its stake in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after purchasing an additional 1,250,000 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of scPharmaceuticals during the third quarter valued at approximately $75,000. XTX Topco Ltd bought a new position in shares of scPharmaceuticals during the third quarter valued at approximately $124,000. Finally, Suvretta Capital Management LLC bought a new position in shares of scPharmaceuticals during the third quarter valued at approximately $9,343,000. 89.52% of the stock is currently owned by institutional investors.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.